Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks

Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks

Kinase is one of the most productive classes of established targets, but the majority of approved drugs against kinase were developed only for cancer. Intensive efforts were therefore exerted for releasing its therapeutic potential by discovering new therapeutic area. Kinases in clinical trial could...

Full description

Bibliographic Details
Main Authors:	Jingyu Xu, Panpan Wang, Hong Yang, Jin Zhou, Yinghong Li, Xiaoxu Li, Weiwei Xue, Chunyan Yu, Yubin Tian, Feng Zhu
Format:	Article
Language:	English
Published:	Hindawi Limited 2016-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2016/2509385

Similar Items

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
by: Jonas Cicenas, et al.
Published: (2021-02-01)

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
by: Krakauer T
Published: (2017-05-01)

Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar
Published: (2008-01-01)

The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
by: Ying Hong Li, et al.
Published: (2016-01-01)

Primary identification of compounds targeting hepatitis B virus capsid formation from the FDA approved drugs
by: YUAN Yi, et al.
Published: (2019-06-01)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
by: Hualou Liang, et al.
Published: (2021-05-01)

Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells
by: Sandipan Datta, et al.
Published: (2021-01-01)

Announcement Effect of Drug Approvals by FDA
by: Ting, Hsiu Wen, et al.
Published: (2008)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
by: Catalin Constantinescu, et al.
Published: (2020-09-01)

Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens
by: Maytham Hussein, et al.
Published: (2020-01-01)

Identification of FDA-approved antivirulence drugs targeting the Pseudomonas aeruginosa quorum sensing effector protein PqsE
by: Valerio Baldelli, et al.
Published: (2020-01-01)

The role of KRAS gene in combination treatment of Curcumin and FDA-approved Targeted Drugs in human colorectal cancer cells
by: Wu, Chi-Shiuan, et al.
Published: (2016)

Signal Separation and Target Localization for FDA Radar
by: Chuanzhi Wang, et al.
Published: (2020-01-01)

Molecular docking, molecular dynamics and MM/PBSA studies of FDA approved drugs for protein kinase a of Mycobacterium tuberculosis; application insights of drug repurposing
by: Shobana Sundar, et al.
Published: (2019-01-01)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
by: Annie Mayence, et al.
Published: (2019-03-01)

Why did the FDA approve these advertisements?
by: David Oaks
Published: (2006-02-01)

FDA approved ready to use phenylephrine
by: Pradeep Kumar Bhatia, et al.
Published: (2021-01-01)

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
by: Olivier Tshiani Mbaya, et al.
Published: (2021-08-01)

One and done: Reasons principal investigators conduct only one FDA-regulated drug trial
by: Amy Corneli, PhD, MPH, et al.
Published: (2017-06-01)

Combinatorial effects of six FDA approved drugs on influenza virus
by: En-Kai Chang, et al.
Published: (2018)

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
by: Ying Jin, et al.
Published: (2020-06-01)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
by: Daniel A. Rodrigues, et al.
Published: (2019-05-01)

The current landscape of the FDA approved companion diagnostics
by: Jan Trøst Jørgensen
Published: (2021-06-01)

Targeting the nsp2 Cysteine Protease of Chikungunya Virus Using FDA Approved Library and Selected Cysteine Protease Inhibitors
by: Prateek Kumar, et al.
Published: (2019-08-01)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
by: Becky A. S. Bibby, et al.
Published: (2021-07-01)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
by: Jeeyun A. Kim, et al.
Published: (2021-03-01)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
by: Gayatri Ramakrishnan, et al.
Published: (2017-07-01)

2020 FDA/EMA approvals for new immunotherapy drug technologies and applications
by: Maryam Monajati, et al.
Published: (2021-06-01)

Detection of Subsurface Target Based on FDA-MIMO Radar
by: Qinghua Liu, et al.
Published: (2018-01-01)

Target Detection Performance Analysis of FDA-MIMO Radar
by: Yu Zhu, et al.
Published: (2019-01-01)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
by: Yikun Mei, et al.
Published: (2020-06-01)

Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
by: Hua-Long Xiong, et al.
Published: (2021-02-01)

FDA efficiency for approval process of COVID-19 therapeutics
by: Christine Cassidy, et al.
Published: (2020-12-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2021-12-01)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
by: Hao Zhong, et al.
Published: (2018-12-01)

THPdb: Database of FDA-approved peptide and protein therapeutics.
by: Salman Sadullah Usmani, et al.
Published: (2017-01-01)

An evaluation and comparison of current FDA-approved treatments for obesity
by: Bapatla, Neha
Published: (2018)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
by: Ernestina Marianna De Francesco, et al.
Published: (2019-08-01)

Utrophin A Upregulation by FDA-Approved Drugs for the Treatment of Duchenne Muscular Dystrophy
by: Péladeau, Christine
Published: (2019)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2021-01-01)